News | May 23, 2023
Freenome acquires global immunodiagnostics developer Oncimmune
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Nous-209 has been developed using the Nouscom's viral vector platform
Bridging the gap between histopathology and molecular pathology
From cancer research to diagnostic solutions
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated
